Business
Currency:USD
2024/Q2
Stock NameRevenueRatio
BRUKINSA®637.4M68.60%
Tislelizumab158.41M17.05%
XGEVA®55.05M5.93%
BLINCYTO®19.13M2.06%
KYPROLIS®15.94M1.71%
Other14.51M1.56%
POBEVCY®11.57M1.25%
REVLIMID®9.13M0.98%
Collaboration revenue8.02M0.86%
View all
Region
Currency:USD
2023/FY
Stock NameRevenueRatio
U.S.1.13B45.89%
China1.1B44.82%
Rest of world202.01M8.22%
Europe26.6M1.08%
